← Back to patent-cliff list
AZD-2693
Tier C — Watch / tradeAZD-2693
Ionis Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：1-acylglycerol-3-phosphate O-acyltransferase PNPLA3
Indications (approved)：Non-alcoholic steatohepatitis, Liver cirrhosis, 代谢病, Hepatic function decline
Regional status
US
Phase II
2023-05-16
EU
Phase II
2023-05-16
China
Discontinued
2024-01-12
Japan
Phase II
2023-05-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZD-2693?
Approved indications include: Non-alcoholic steatohepatitis, Liver cirrhosis, 代谢病, Hepatic function decline.
When does the AZD-2693 patent expire?
No public expiry year is available for AZD-2693 yet; this page updates once verified.
How do I get a quote for AZD-2693 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03